Search
Europe Leads the Way in Authorizing Moderna’s Innovative mRNA Dual Vaccine for Influenza and COVID-19
1 day ago /
Read about 0 minute
Author：小编
Moderna’s groundbreaking mRNA combination vaccine, mRNA‑1083 (marketed as mCOMBRIAX), has recently secured approval for commercialization in Europe, marking its status as the world’s first dual-action vaccine formulation designed to simultaneously guard against both influenza and COVID-19. Earlier, the vaccine had garnered a favorable scientific opinion from the pertinent committee of the European Medicines Agency, effectively clearing the path for its authorization across the European Union. Notably, this vaccine, which originated from research and development efforts in the United States, has yet to achieve marketing clearance within its country of origin.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
